Next Article in Journal
Innate Immunity in Insects: The Lights and Shadows of Phenoloxidase System Activation
Next Article in Special Issue
Galectin-3 and Pentraxin-3 as Potential Biomarkers in Chronic Coronary Syndrome and Atrial Fibrillation: Insights from a 131-Patient Cohort
Previous Article in Journal
MFP-MFL: Leveraging Graph Attention and Multi-Feature Integration for Superior Multifunctional Bioactive Peptide Prediction
Previous Article in Special Issue
Alleviating the Effects of Short QT Syndrome Type 3 by Allele-Specific Suppression of the KCNJ2 Mutant Allele
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Lower Concentration of Plasma Acetyl-Carnitine in Epicardial Artery Disease—A Preliminary Report

by
Tomasz Urbanowicz
1,*,
Paweł Gutaj
2,
Szymon Plewa
3,
Anna Olasińska-Wiśniewska
1,
Ievgen Spasenenko
4,
Beata Krasińska
4,
Andrzej Tykarski
4,
Krzysztof J. Filipiak
4,5,
Martyna Pakuła-Iwańska
4,
Zbigniew Krasiński
6,
Ewelina Grywalska
7,
Ewa Wender-Ożegowska
2,
Marek Jemielity
1 and
Jan Matysiak
2
1
Cardiac Surgery and Transplantology Department, Poznan University of Medical Sciences, 61-701 Poznan, Poland
2
Department of Reproduction, Poznan University of Medical Sciences, 61-701 Poznan, Poland
3
Department of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, 61-701 Poznan, Poland
4
Department of Hypertensiology, Angiology and Internal Medicine, University of Medical Sciences, 61-701 Poznan, Poland
5
Institute of Clinical Science, Maria Sklodowska-Curie Medical Academy, 00-136 Warsaw, Poland
6
Department of Vascular, Endovascular Surgery, Angiology and Phlebology Medical University, Poznan University of Medical Science, 61-701 Poznan, Poland
7
Department of Experimental Immunology, Medical University of Lublin, Chodzki Street, 20-059 Lublin, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(3), 1318; https://doi.org/10.3390/ijms26031318
Submission received: 30 December 2024 / Revised: 27 January 2025 / Accepted: 31 January 2025 / Published: 4 February 2025

Abstract

Coronary artery disease remains an epidemiological challenge as global morbidity is not declining despite the fact that the risk factors are well known. Metabolomic derivatives of atherosclerosis formation have recently gained attention as a possible non-traditional risk factor. The aim of this study was to find potential differences in acetyl-carnitine chain serum concentrations between epicardial artery disease patients and a control group. There were 41 patients (25 men and 16 women), with a median (Q1–Q3) age of 69 (63–73) years, enrolled in the prospective metabolomic analysis. They were divided into two groups based on cine angiography results confirming epicardial artery disease (group 1, n = 25 (61%)) or showing characteristics corresponding to normal angiograms (group 2, n = 16 (39%)). The quantitation of metabolites was performed based on the coronary angiograms. Significant differences related to the plasma concentration of L-Acetyl-carnitine (7.49 (4.79–9.23) µM vs. 9.36 (8.57–10.23) µM (p = 0.009)), Decanoyl-carnitine (0.00 (0.00–0.37) µM vs. 0.36 (0.19–0.44) µM (p = 0.040)), C12:1-carnitine (0.17 (0.14–0.20) µM vs. 0.22 (0.18–0.24) µM (p = 0.008)), trans-2-Dodecenoyl-carnitine (0.10 (0.07–0.13) µM vs. 0.13 (0.10–0.15) µM (p = 0.002)), cis-5-Tetradecenoyl-carnitine (0.03 (0.02–0.04) µM vs. 0.04 (0.03–0.05) µM (p = 0.043)), and 3,5-Tetradecadien-carnitine (0.16 (0.14–0.18) µM vs. 0.18 (0.17–0.27) µM (p = 0.007)) in group 1 vs. group 2 were noted. Increased plasma levels of acetyl-carnitine may be characteristic of patients with normal coronary angiograms.

1. Introduction

Coronary artery disease (CAD) remains an epidemiological challenge, as global morbidity is not declining even though the risk factors are well-known [1]. The genetic factors, along with environment and lifestyle, are linked with an increased risk of cardiovascular disease development [2]. There is a high prevalence of subclinical epicardial disease in the general population despite proposed screening tests and improved risk stratification [3]. The cornerstone for effective prevention is properly assessing atherosclerotic cardiovascular disease threats [4]. Non-traditional risk factors are presently being thoroughly investigated to improve long-term outcomes.
As cardiovascular disease jeopardy prediction is an under-addressed clinical subject, exploring novel prognostic factors, including metabolic biomarkers, is raising interest. Atherosclerotic disease is considered a chronic inflammatory condition [5,6,7], for which anti-inflammatory therapeutic approaches have recently gained attention [8,9].
A marked heterogeneous presentation, including chronic and acute stages and various forms between them, characterizes CAD. While classical markers, such as troponin or brain natriuretic peptide (BNP), are useful for patients with heart dysfunction, metabolomic molecules have recently gathered even more interest as experimental features of impaired metabolic flexibility. The early detection of markers associated with an increased risk of cardiovascular events would be crucial in clinical practice. Lv et al. [10] suggested adding metabolomic parameters to the tailed risk assessment of acute cardiovascular events. Middle- and long-chain acetyl-carnitines have been identified as being associated with cardiovascular death, myocardial infarction, and stroke. Among the naturally occurring amino acids characterized by anti-inflammatory effects is L-carnitine, which is believed to influence the cardiovascular system considerably [11]. Previous studies [11] suggested l-carnitine (LC) supplementation had a beneficial effect on oxidative stress and inflammatory biomarkers in patients with CAD. Gander et al. [12] indicated a mitochondrial imbalance exists in patients with coronary artery disease based on altered acetyl-carnitine levels. A relationship between short-chain acetyl-carnitine serum concentration and heart failure was suggested in the DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients with HF with Reduced Ejection Fraction) trial [13]. The influence of obesity and dietary habits on plasma acetyl-carnitine and heart failure risk was reported by France et al. [14]. The role of specific metabolites in the metabolic pathways and their differences in various disease presentations is still unclear.
The aim of the study was to find potential differences in acetyl-carnitine chain serum concentrations between epicardial artery disease patients and a control group.

2. Results

Patients were divided into two groups based on cine angiography results confirming epicardial artery disease (group 1, n = 25 (61%)) or resulting exhibiting characteristics corresponding to normal angiograms (group 2, n = 16 (39%)). The demographic and clinical characteristics are presented in Table 1.
The cine-angiography, echocardiographic, and laboratory test results were compared between both groups, as presented in Table 2.
A metabolomic evaluation of carnitine in the analyzed population was performed, and the results were compared between groups. The 20 types of acetyl-carnitine plasma concentrations were investigated.
The following explored parameters were not incorporated into the analysis as they did not reach the LOD value: Hydroxypropionyl-carnitine, Propenoyl-carnitine, 3-Methylglutaryl-carnitine, Tiglyl-carnitine, Glutaconyl-carnitine, 2-Hexenoyl-carnitine, 2,6 Dimethylheptanoyl-carnitine/Nonanoyl-carnitine, Dodecanoyl-carnitine, Dodecanedioylcarnitine, Tetradecanoylcarnitine, 3-Hydroxy-cis-5-tetradecenoylcarnitine, Palmitoyl-carnitine, 3-Hydroxyhexadecanoyl-carnitine, trans-Hexadec-2-enoyl-carnitine/9-Hexadecenoyl-carnitine, 3-Hydroxy-9-hexadecenoy-lcarnitine, 9,12-Hexadecadienoyl-carnitine, 3-Hydroxyhexadecadienoyl-carnitine, Stearoyl-carnitine, and 3-Hydroxy-11Z-octadecenoyl-carnitine. As only one positive sample of 9-Decenoyl-carnitine and two positive samples of Hexanoylcarnitine were obtained, these parameters were not considered. The plasma acetyl-carnitine chains that were incorporated into the analysis are presented in Table 3.
Significant differences related to the plasma concentrations of L-Acetylcarnitine between the CAD group and the non-CAD group were noted, as presented in Figure 1, Figure 2, Figure 3, Figure 4, Figure 5 and Figure 6.
In the analyzed groups, we found significant differences regarding high-density lipoprotein (p = 0.010) but not total cholesterol (p = 0.466), low-density lipoprotein (p = 0.762), or triglycerides (p = 0.803).
We noticed a positive correlation between various acetyl-carnitine types but not lipidogram components, including HDL, as presented in Figure 7.
As males are predisposed to developing CAD disease, we compared the acetyl-carnitine results related to the male sex via rank-biserial correlation, as presented in Table 4. The results revealed significant sex-related differences for CAD predisposition related to L-Acetyl-carnitine (p = 0.036), Decanoyl-carnitine (p = 0.003), trans-2-Dodecenoyl-carnitine (p = 0.10), cis-5-Tetradecenoyl-carnitine (p = 0.011), and Oleoyl-carnitine/Vaccenyl-carnitine/Elaidic-carnitine (p = 0.035), as presented in Table 4.

3. Discussion

The results of our analysis point out the significantly lower plasma concentrations of low-chain acetyl-carnitine in coronary artery patients. The presented decreases were found to be independent of the lipogram results. The suggested scenario of atherosclerosis development may be regarded as unrelated to lipid-dependent pathways.
Our study enables an understanding of the molecular aspects involved in different clinical presentations of cardiovascular diseases. Our study population included patients with stable coronary artery disease and controls; both groups were burdened with the classical cardiovascular risk. However, the metabolomic profiles differed between them.
Carnitine is a naturally occurring amino acid required to transport long-chain fatty acids into mitochondria, indicating its significant function in fat metabolism [15]. In animal studies [16], it has been shown that metabolic reprogramming via abolishing the fatty acid oxidation of cardiomyocytes may improve their resistance to hypoxia and stimulate cardiomyocyte proliferation, allowing heart regeneration. The anti-inflammatory properties of carnitine, combined with its antioxidant function as a scavenger of free radicals, were suggested in previous studies [17]. In randomized studies, carnitine was shown to be beneficial by increasing antioxidant enzyme activities and reducing oxidative stress [18].
Our analysis revealed significantly lower plasma concentrations of C2, an acetylated derivative of the amino acid L-carnitine whose function is related to energy metabolism regulation within mammalian mitochondria [19]. This acetic acid ester of carnitine plays a role in fatty acid metabolism by accelerating acetyl-CoA into the matrices of mitochondria during the oxidation of fatty acids [20]. The role of acid L-carnitine in neuropathophysiology has been widely reported [21,22], but its relation to coronary artery disease is inconclusive [23,24].
Significant differences between the CAD and non-CAD groups regarding sC10, which stands for decanoyl-carnitine, were noted in our report. It is a decanoic acid ester of carnitine. It is a medium-chain acylcarnitine [19]. It is formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer-chain acylcarnitines [25]. It has been proposed to be a useful marker for inherited fatty acid metabolism disorders, especially for hypertensive patients [26].
A higher concentration of the trans-2-dodecenoic acid ester of carnitine, an acetyl-carnitine denoted as C12:1, in the control group was reported in our analysis. This medium-chain acylcarnitine trans-2-dodecenoyl-carnitine’s role in pathophysiology is not very well known, though previous reports have indicated its possible role in oncology and inflammatory processes [27,28].
The other acetyl-carnitine that differentiated our groups was cis-5-Tetradecenoyl-carnitine, listed as C14:1. It is classified as a long-chain AC and forms through esterification with fatty acids obtained from one’s diet. Increased plasma levels have also been observed in patients who have lost weight [29]. A higher plasma content was characteristic of non-coronary-disease patients in our study.
A higher plasma concentration of 3,5-Tetradecadien-carnitine, denoted as C14:2, was noted in our analysis. This is another long-chain AC who’s main function is related to the transport of fatty acids into the mitochondria [30]. Our analysis brings a new perspective on the possible role of this long-chain AC in cardiovascular pathology.
Oleoyl-carnitine, Vaccenyl-carnitine, and Elaidic-carnitine are long-chain carnitines whose concentrations in plasma are diet-dependent. Fatty acid derivative accumulation was postulated to play a role in Vaccenyl-carnitine deficiency, representing one of the most common inherited lipid metabolism disorders [31]. Elastic carnitine deficiency was reported to cause fatal effects related to profound disturbances in fatty acid oxygenation [32].
Our metabolomics analysis suggests a new role of acetyl-carnitine short-, medium-, and long-chain esters arising from the conjugation of acyl chains to the hydroxyl group of L-carnitine in the possible pathophysiology of coronary artery disease (besides lipid disturbances). The sex-related differences in CAD prevalence were also confirmed via acyl-carnitine concentrations, which may suggest the fairness of our hypothesis.
Previous studies have reported altered levels of acetyl-carnitines in patients with myocardial injury, reflected in heart failure with a reduced ejection fraction [33], and a decrease in patients treated with mechanical support [34]. We examined a study population burdened with a significant cardiovascular risk. Patients treated pharmacologically who presented with a stable form of coronary artery disease had lower levels of acetyl-carnitines, which may shed light on the impact of the disease stage on metabolomic profiles. Further, larger-scale studies comparing metabolomic markers in patients with different stages of coronary artery disease with and without heart failure are necessary.

4. Study Limitations

This study was performed on a limited number of patients who corresponded to the typical clinical scenario for coronary artery disease, with a prevalence of the male sex. The results were compared with chronic coronary syndrome patients and normal cine angiograms. Due to the limited number of participants, the preliminary report indicated the differences between the coronary and non-coronary disease populations were related to acetyl-carnitine serum concentrations but not other potential factors. The insignificant differences regarding the clinical data suggest a possible novel epicardial artery atherosclerotic plaque formation pathway.

5. Methods

5.1. Patients

A total of 41 consecutive patients (25 men and 16 women), with a median (Q1–Q3) age of 69 (63–73) years, were enrolled in the prospective metabolomic analysis. They presented with chronic coronary syndrome (CCS) class (2 ± 0.3) and were hospitalized in the internal medicine and hypertension department from 2022 to 2024. To present the real-life results for a limited number of participants, consecutive patients admitted for coronary angiograms were incorporated into the analysis. Patients with inflammatory and neoplasm diseases were excluded. Clinical and demographic data were recorded. The co-morbidities in the presented group included arterial hypertension (33 (81%)) and dyslipidemia (33 (81%)), followed by diabetes mellitus (11 (27%)), chronic obstructive pulmonary disease (6 (15%)), kidney dysfunction (4 (10%)), and peripheral artery disease (3(7%)). Patients were divided into two groups based on cine angiography results confirming epicardial artery disease (CAD group 1, n = 25 (61%)) or showing characteristics corresponding to normal angiograms (non-CAD group 2, n = 16 (39%)) (Figure 8).
A clinical evaluation was performed during hospitalization, followed by transthoracic echocardiography, cine-angiography, and laboratory tests. Additionally, peripheral blood samples were taken for metabolomics analyses.

5.2. Methods

The methods employed included laboratory data analysis comprising whole blood count parameters using a routine hematology analyzer (Sysmex Europe GmbH, Norderstedt, Germany).
Anthropometric measurements were obtained using a Marsden M-100 Column Scale with Height Measure (Charder Electronics, Co. Ltd., London, UK).
The quantitation of metabolites was performed using the AbsoluteIDQ p180 kit (Biocrates LifeSciences AG, Innsbruck, Austria). All compounds were analyzed using a single sample preparation procedure. For single sample determination, the 10 µL of serum was used. The samples were prepared according to the manufacturer’s instructions. The samples were analyzed in a blind manner in a random order. The filter layer, pre-pipetted by the manufacturer, contained stable isotope labeled internal standards (ISs). The remaining ISs were prepared as per the manufacturer’s guidelines and pipetted onto a kit plate. Then, calibrators and quality control (QC) samples were prepared and put onto a plate. Then, 10 μL aliquots of thawed serum samples were pipetted onto the filter layer of a 96-deep well plate, and the plate was dried under nitrogen flow for 30 min. After that, the freshly prepared derivatization solution was pipetted onto the plate and incubated under a cover for 25 min. Then, the plate was dried under nitrogen flow (60 min). The extraction solvent was added to each well in the next step, and the plate was shaken for 30 min (450 rpm). The extracts were further pushed through the filter layer using nitrogen flow. The obtained extracts were divided into two separate 96-well plates and diluted according to the manufacturer’s specifications. After being sealed with silicone naps, the plates were put into a thermostatic autosampler.
The metabolites were analyzed using a liquid chromatography–tandem mass spectrometry system (LC-MS/MS) that combines a 1260 Infinity HPLC (Agilent Technologies, Santa Clara, CA, USA) liquid chromatograph with a 4000QTRAP mass spectrometer (SCIEX, Framingham, MA, USA). The compounds were analyzed using flow injection analysis (FIA-MS/MS method). Two groups of chemical compounds, which have already been covered in the Methods Section (amino acids and biogenic amines), were separated prior to detection by the use of a ZORBAX Eclipse XDB-C18 (3.0 × 100 mm, 3.5 μm) column (Agilent Technologies, Santa Clara, CA, USA), with a pre-column (C18, 4.0 × 3.0 mm) SecurityGuard (Phenomenex, Torrance, CA, USA) and mass spectrometry detection and quantitation.
The data acquisition process was performed using Analyst 1.6.3 software (Sciex, Framingham, MA, USA). Data processing, integration, calibration, and evaluation were performed using WebIDQ software (Biocrates LifeSciences AG, Innsbruck, Austria).

5.3. Statistical Analysis

The Shapiro–Wilk test was used to assess the normality of data distribution. According to the test result, clinical and biochemical continuous variables were presented as medians and interquartile ranges [Q1–Q3] and compared using the non-parametric Mann–Whitney test. Where applicable, categorical data were expressed as numbers and percentages and compared using Fisher’s exact test or Chi-square test. Spearman correlation analysis was used to describe the correlation between the variables. GPower (version 3.1.9.2; Institute for Experimental Psychology in Dusseldorf, Germany) testing was applied to calculate the sample size. Based on the assumption of an undetermined target population size, with α = 0.05 and β = 0.2, the minimum sample size was estimated to be 24 participants. Hence, we decided to collect complete data from at least 25 participants and a roughly equivalent number of controls.
To compare the results obtained for the CAD male population with the rest of the analyzed groups, a rank-share real correlation with 95% confidence intervals was applied. Statistical analysis was performed using JASP software [JASP Team; 2023. Version 0.18.1]. p < 0.05 was considered statistically significant (https://jasp-stats.org, accessed on 15 December 2024).

5.4. Bioethics Committee

The Institutional Ethics Committee of Poznan University of Medical Sciences, Poznan, Poland (protocol code 694/20 on 4 November 2020), approved this study, which was conducted in accordance with the principles outlined in the Declaration of Helsinki.

6. Conclusions

Increased plasma levels of acetyl-carnitine may characterize patients with normal coronary angiograms. In our preliminary report, we noticed significantly lower plasma levels of L-Acetyl-carnitine, Decanoyl-carnitine C12:1, trans-2-Dodecenoyl-carnitine, cis-5-Tetradecenoyl-carnitine, and 3,5-Tetradecadien-carnitine in patients presenting with angiography-proven coronary disease. The metabolomic results could indicate a novel, non-lipid-dependent pathway of coronary atherosclerosis development. Further studies are required to confirm the suggested hypothesis.

Author Contributions

Conceptualization, T.U. and S.P.; methodology, S.P. and J.M.; software, S.P.; validation, T.U., A.O.-W., S.P. and J.M.; formal analysis, T.U.; investigation, T.U., P.G., E.W.-O., A.O.-W., I.S., E.W.-O., P.G. and M.P.-I.; resources, I.S. and B.K.; data curation, I.S., P.G. and M.P.-I.; writing—original draft preparation, T.U.; writing—review and editing, P.G., E.W.-O., B.K., A.T., K.J.F., Z.K., E.G., M.J. and J.M.; visualization, T.U.; supervision, A.T. and M.J.; project administration, J.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki, and it was approved by the Ethics Committee of Poznan University of Medical Sciences, Poznan, Poland (protocol code 694/20 on 4 November 2020), for studies involving humans.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data supporting this study’s results will be shared for three years after publication by the corresponding author via e-mail upon making a reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Al-Lamee, R.K. Agina pectoris 2023: With and without obstructive coronary artery disease: Epidemiology, diagnosis, prognosis, and treatment. Vasc. Pharmacol. 2024, 155, 107285. [Google Scholar] [CrossRef]
  2. Malakar, A.K.; Choudhury, D.; Halder, B.; Paul, P.; Uddin, A.; Chakraborty, S. A review on coronary artery disease, its risk factors, and therapeutics. J. Cell. Physiol. 2019, 234, 16812–16823. [Google Scholar] [CrossRef] [PubMed]
  3. Saraste, A.; Knuuti, J.; Bax, J. Screening for Coronary Artery Disease in Patients with Diabetes. Curr. Cardiol. Rep. 2023, 25, 1865–1871. [Google Scholar] [CrossRef]
  4. Goldsborough, E., 3rd; Osuji, N.; Blaha, M.J. Assessment of Cardiovascular Disease Risk: A 2022 Update. Endocrinol. Metab. Clin. N. Am. 2022, 51, 483–509. [Google Scholar] [CrossRef]
  5. Gusev, E.; Sarapultsev, A. Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes. Int. J. Mol. Sci. 2023, 24, 7910. [Google Scholar] [CrossRef]
  6. Urbanowicz, T.; Olasińska-Wiśniewska, A.; Michalak, M.; Perek, B.; Al-Imam, A.; Rodzki, M.; Witkowska, A.; Straburzyńska-Migaj, E.; Bociański, M.; Misterski, M.; et al. Pre-operative systemic inflammatory response index influences long-term survival rate in off-pump surgical revascularization. PLoS ONE 2022, 17, e0276138. [Google Scholar] [CrossRef] [PubMed]
  7. Urbanowicz, T.K.; Rodzki, M.; Michalak, M.; Olasińska-Wiśniewska, A.; Witkowska, A.; Krasińska, B.; Bociański, M.; Krasińska-Płachta, A.; Cieśla, A.; Stefaniak, S.; et al. Large unstained cell (LUC) count as a predictor of carotid artery occlusion. Adv. Clin. Exp. Med. 2023, 32, 987–996. [Google Scholar] [CrossRef]
  8. Ridker, P.M. The Time to Initiate Anti-Inflammatory Therapy for Patients with Chronic Coronary Atherosclerosis Has Arrived. Circulation 2023, 148, 1071–1073. [Google Scholar] [CrossRef] [PubMed]
  9. Grajek, S.; Michalak, M.; Urbanowicz, T.; Olasińska-Wiśniewska, A. A Meta-Analysis Evaluating the Colchicine Therapy in Patients with Coronary Artery Disease. Front. Cardiovasc. Med. 2021, 8, 740896. [Google Scholar] [CrossRef]
  10. Lv, J.; Pan, C.; Cai, Y.; Han, X.; Wang, C.; Ma, J.; Pang, J.; Xu, F.; Wu, S.; Kou, T.; et al. Plasma metabolomics reveals the shared and distinct metabolic disturbances associated with cardiovascular events in coronary artery disease. Nat. Commun. 2024, 15, 5729–5742. [Google Scholar] [CrossRef]
  11. Rastgoo, S.; Fateh, S.T.; Nikbaf-Shandiz, M.; Rasaei, N.; Aali, Y.; Zamani, M.; Shiraseb, F.; Asbaghi, O. The effects of L-carnitine supplementation on inflammatory and anti-inflammatory markers in adults: A systematic review and dose-response meta-analysis. Inflammopharmacology 2023, 31, 2173–2199. [Google Scholar] [CrossRef] [PubMed]
  12. Gander, J.; Carrard, J.; Gallart-Ayala, H.; Borreggine, R.; Teav, T.; Infanger, D.; Colledge, F.; Streese, L.; Wagner, J.; Klenk, C.; et al. Metabolic Impairment in Coronary Artery Disease: Elevated Serum Acylcarnitines Under the Spotlights. Front. Cardiovasc. Med. 2021, 8, 792350. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  13. Selvaraj, S.; Fu, Z.; Jones, P.; Kwee, L.C.; Windsor, S.L.; Ilkayeva, O.; Newgard, C.B.; Margulies, K.B.; Husain, M.; Inzucchi, S.E.; et al. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Circulation 2022, 146, 808–818. [Google Scholar] [CrossRef] [PubMed]
  14. Franco, A.D.; Morfino, P.; Aimo, A. Plasma acylcarnitine, risk for heart failure or atrial fibrillation, and effects of the Mediterranean diet or obesity. Rev. Esp. Cardiol. (Engl. Ed.) 2022, 75, 621–622. [Google Scholar] [CrossRef]
  15. Shah, P.; Sawhney, A.; Anamika, F.; Kanagala, S.G.; Parikh, K.; Mendpara, V.; Garg, N.; Jain, R. Understanding the Relationship between the Ketogenic Diet and the Heart: A Novel Therapeutic Potential for Cardiovascular Health. Cardiovasc. Hematol. Agents Med. Chem. 2024, 22, 407–412. [Google Scholar] [CrossRef]
  16. Li, X.; Wu, F.; Günther, S.; Looso, M.; Kuenne, C.; Zhang, T.; Wiesnet, M.; Klatt, S.; Zukunft, S.; Fleming, I.; et al. Inhibition of fatty acid oxidation enables heart regeneration in adult mice. Nature 2023, 622, 619–626. [Google Scholar] [CrossRef]
  17. Shang, R.; Sun, Z.; Li, H. Effective dosing of L-carnitine in the secondary prevention of cardiovascular disease: A systematic review and meta-analysis. BMC Cardiovasc. Disord. 2014, 14, 88–95. [Google Scholar] [CrossRef]
  18. Lee, B.J.; Lin, J.S.; Lin, Y.C.; Lin, P.T. Effects of L-carnitine supplementation on oxidative stress and antioxidant enzymes activities in patients with coronary artery disease: A randomized, placebo-controlled trial. Nutr. J. 2014, 13, 79–96. [Google Scholar] [CrossRef]
  19. Dambrova, M.; Makrecka-Kuka, M.; Kuka, J.; Vilskersts, R.; Nordberg, D.; Attwood, M.M.; Smesny, S.; Sen, Z.D.; Guo, A.C.; Oler, E.; et al. Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials. Pharmacol. Rev. 2022, 74, 506–551. [Google Scholar] [CrossRef] [PubMed]
  20. Izzo, L.T.; Trefely, S.; Demetriadou, C.; Drummond, J.M.; Mizukami, T.; Kuprasertkul, N.; Farria, A.T.; Nguyen, P.T.T.; Murali, N.; Reich, L.; et al. Acetylcarnitine shuttling links mitochondrial metabolism to histone acetylation and lipogenesis. Sci. Adv. 2023, 9, eadf0115. [Google Scholar] [CrossRef] [PubMed]
  21. Sassi, S.; Bianchi, E.; Diamanti, L.; Tornabene, D.; Sette, E.; Medici, D.; Matà, S.; Leccese, D.; Sperti, M.; Martinelli, I.; et al. Retrospective observational study on the use of acetyl-L-carnitine in ALS. J. Neurol. 2023, 270, 5344–5357. [Google Scholar] [CrossRef] [PubMed]
  22. Ait Tayeb, A.E.K.; Colle, R.; El-Asmar, K.; Chappell, K.; Acquaviva-Bourdain, C.; David, D.J.; Trabado, S.; Chanson, P.; Feve, B.; Becquemont, L.; et al. Plasma acetyl-l-carnitine and l-carnitine in major depressive episodes: A case-control study before and after treatment. Psychol. Med. 2023, 53, 2307–2316. [Google Scholar] [CrossRef]
  23. Zhao, J.V.; Burgess, S.; Fan, B.; Schooling, C.M. L-carnitine, a friend or foe for cardiovascular disease? A Mendelian randomization study. BMC Med. 2022, 20, 272–282. [Google Scholar] [CrossRef] [PubMed]
  24. Jiang, H.; Li, L.; Chen, W.; Chen, B.; Li, H.; Wang, S.; Wang, M.; Luo, Y. Application of Metabolomics to Identify Potential Biomarkers for the Early Diagnosis of Coronary Heart Disease. Front Physiol. 2021, 12, 775135. [Google Scholar] [CrossRef]
  25. Violante, S.; Achetib, N.; van Roermund, C.W.T.; Hagen, J.; Dodatko, T.; Vaz, F.M.; Waterham, H.R.; Chen, H.; Baes, M.; Yu, C.; et al. Peroxisomes can oxidize medium- and long-chain fatty acids through a pathway involving ABCD3 and HSD17B4. FASEB J. 2019, 33, 4355–4364. [Google Scholar] [CrossRef]
  26. Cho, K.; Moon, J.S.; Kang, J.H.; Jang, H.B.; Lee, H.J.; Park, S.I.; Yu, K.S.; Cho, J.Y. Combined untargeted and targeted metabolomic profiling reveals urinary biomarkers for discriminating obese from normal-weight adolescents. Pediatr. Obes. 2017, 12, 93–101. [Google Scholar] [CrossRef]
  27. Liu, X.; Cheng, X.; Liu, X.; He, L.; Zhang, W.; Wang, Y.; Sun, W.; Ji, Z. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery. Int. J. Cancer 2018, 143, 408–418. [Google Scholar] [CrossRef] [PubMed]
  28. Maerz, T.; Sherman, E.; Newton, M.; Yilmaz, A.; Kumar, P.; Graham, S.F.; Baker, K.C. Metabolomic serum profiling after ACL injury in rats: A pilot study implicating inflammation and immune dysregulation in post-traumatic osteoarthritis. J. Orthop. Res. 2018, 36, 1969–1979. [Google Scholar] [CrossRef]
  29. Kang, M.; Yoo, H.J.; Kim, M.; Kim, M.; Lee, J.H. Metabolomics identifies increases in the acylcarnitine profiles in the plasma of overweight subjects in response to mild weight loss: A randomized, controlled design study. Lipids Health Dis. 2018, 17, 237–240. [Google Scholar] [CrossRef] [PubMed]
  30. Reuter, S.E.; Evans, A.M. Carnitine and acylcarnitines: Pharmacokinetic, pharmacological and clinical aspects. Clin. Pharmacokinet. 2012, 51, 553–572. [Google Scholar] [CrossRef] [PubMed]
  31. Shen, J.J.; Matern, D.; Millington, D.S.; Hillman, S.; Feezor, M.D.; Bennett, M.J.; Qumsiyeh, M.; Kahler, S.G.; Chen, Y.T.; Van Hove, J.L. Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders. J. Inherit. Metab. Dis. 2000, 23, 27–44. [Google Scholar] [CrossRef] [PubMed]
  32. Pierre, G.; Macdonald, A.; Gray, G.; Hendriksz, C.; Preece, M.A.; Chakrapani, A. Prospective treatment in carnitine-acylcarnitine translocase deficiency. J. Inherit. Metab. Dis. 2007, 30, 815–820. [Google Scholar] [CrossRef] [PubMed]
  33. Harada, H.; Nishiyama, Y.; Katoh, A.; Niiyama, H.; Iwaki, A.; Ohchi, Y.; Sasaki, M.; Aoki, Y.; Okina, N.; Kai, H. Heart failure treatment and serum carnitines in HFpEF and HFrEF with or without hypertension—A pilot study. Hypertens. Res. 2025. epub ahead of print. [Google Scholar] [CrossRef]
  34. Ahmad, T.; Kelly, J.P.; McGarrah, R.W.; Hellkamp, A.S.; Fiuzat, M.; Testani, J.M.; Wang, T.S.; Verma, A.; Samsky, M.D.; Donahue, M.P.; et al. Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility with Mechanical Circulatory Support. J. Am. Coll. Cardiol. 2016, 67, 291–299. [Google Scholar] [CrossRef] [PubMed]
Figure 1. C2 acetyl-carnitine (L-Acetyl-carnitine) differences in plasma concentration [uM] between CAD group (1) vs non-CAD group (0) (p = 0.009).
Figure 1. C2 acetyl-carnitine (L-Acetyl-carnitine) differences in plasma concentration [uM] between CAD group (1) vs non-CAD group (0) (p = 0.009).
Ijms 26 01318 g001
Figure 2. C10 acetyl-carnitine (Decanoyl-carnitine) differences in plasma concentration [uM] between CAD group (1) vs non-CAD group (0) (p = 0.040).
Figure 2. C10 acetyl-carnitine (Decanoyl-carnitine) differences in plasma concentration [uM] between CAD group (1) vs non-CAD group (0) (p = 0.040).
Ijms 26 01318 g002
Figure 3. C12:1 acetyl-carnitine (trans-2-Dodecenoyl-carnitine) differences in plasma concentration [uM] between CAD group (1) vs non-CAD group (0) (p = 0.008).
Figure 3. C12:1 acetyl-carnitine (trans-2-Dodecenoyl-carnitine) differences in plasma concentration [uM] between CAD group (1) vs non-CAD group (0) (p = 0.008).
Ijms 26 01318 g003
Figure 4. C14:1 acetyl-carnitine (cis-5-Tetradecenoyl-carnitine) differences in plasma concentration [uM] between CAD group (1) vs non-CAD group (0) (p = 0.002).
Figure 4. C14:1 acetyl-carnitine (cis-5-Tetradecenoyl-carnitine) differences in plasma concentration [uM] between CAD group (1) vs non-CAD group (0) (p = 0.002).
Ijms 26 01318 g004
Figure 5. C14:2 acetylcarnitine (3, 5-Tetradecadien-carnitine) differences in plasma concentration [uM] between CAD group (1) vs non-CAD group (0) (p = 0.043).
Figure 5. C14:2 acetylcarnitine (3, 5-Tetradecadien-carnitine) differences in plasma concentration [uM] between CAD group (1) vs non-CAD group (0) (p = 0.043).
Ijms 26 01318 g005
Figure 6. C18:1 acetyl-carnitine (Oleoyl-carnitine/Vaccenyl-carnitine/Elaidic-carnitine) differences in plasma concentration [uM] between CAD group (1) vs non-CAD group (0) (p = 0.007).
Figure 6. C18:1 acetyl-carnitine (Oleoyl-carnitine/Vaccenyl-carnitine/Elaidic-carnitine) differences in plasma concentration [uM] between CAD group (1) vs non-CAD group (0) (p = 0.007).
Ijms 26 01318 g006
Figure 7. Possible correlations between numerous acetyl-carnitines in the CAD group. Velvet and peach colors correspond to positive and negative correlation coefficients, respectively. The saturation of each color reflects the absolute value of the correlation coefficient. *—p < 0.050, **—p < 0.010, and ***—p < 0.001. Abbreviations: C2—L-Acetylcarnitine; C10—Decanoylcarnitine; C12:1—trans-2-Dodecenoylcarnitine; C14:1—cis-5-Tetradecenoylcarnitine; C14:2—3,5-Tetradecadiencarnitine; C18:1—Oleoylcarnitine/Vaccenyl carnitine/Elaidic carnitine; chol—total cholesterol; HDL—high-density lipoprotein; LDL—low-density lipoprotein; TG—triglycerides.
Figure 7. Possible correlations between numerous acetyl-carnitines in the CAD group. Velvet and peach colors correspond to positive and negative correlation coefficients, respectively. The saturation of each color reflects the absolute value of the correlation coefficient. *—p < 0.050, **—p < 0.010, and ***—p < 0.001. Abbreviations: C2—L-Acetylcarnitine; C10—Decanoylcarnitine; C12:1—trans-2-Dodecenoylcarnitine; C14:1—cis-5-Tetradecenoylcarnitine; C14:2—3,5-Tetradecadiencarnitine; C18:1—Oleoylcarnitine/Vaccenyl carnitine/Elaidic carnitine; chol—total cholesterol; HDL—high-density lipoprotein; LDL—low-density lipoprotein; TG—triglycerides.
Ijms 26 01318 g007
Figure 8. Study flowchart. Abbreviations: CAD—coronary artery disease; n—number.
Figure 8. Study flowchart. Abbreviations: CAD—coronary artery disease; n—number.
Ijms 26 01318 g008
Table 1. Demographic and clinical characteristics.
Table 1. Demographic and clinical characteristics.
ParametersWhole Group
n = 41
Group 1
CAD Group
n = 25
Group 2
Non-CAD Group
n = 16
p
Group 1 vs. 2
Demographics
Age (years) (median (Q1–Q3))69 (63–73)69 (63–73)70 (64–74)0.556
Height (cm) (median (Q1–Q3))165 (163–176)167 (164–176)164 (162–176)0.628
Weight (kg) (median (Q1–Q3))80 (70–91)80 (71–92)80 (67–88)0.645
BMI (median (Q1–Q3))28.6 (25.4–31.8)29.1 (25.4–30.9)28.2 (25.5–32.3)0.822
BMI > 3017 (41)10 (40)7 (44)1.000
Clinical status:
CCS class
class I (n (%))1 (2)0 (0)1 (6)
class II (n (%))34 (83)19 (76)15 (94)0.056
class III (n (%))6 156 (24)0 (0)
NYHA class
class I (n (%))23 (56)13 (52)10 (63)
class II (n (%))17 (42)11 (44)6 (37)0.628
class III (n (%))1 (2)1 (4)0 (0)
Co-morbidities:
Arterial hypertension (n (%))35 (85)22 (88)13 (81)0.662
Diabetes mellitus (n (%))12 (29)7 (28)5 (31)1.000
Dyslipidemia (n (%))33 (83)21 (84)13 (81)1.000
COPD (n (%))7 (17)5 (20)2 (13)0.685
Kidney dysfunction * (n (%))5 (12)3 (12)2 (13)1.000
PAD (n (%))4 (10)3 (12)1 (6)1.000
Thyroid disease (n (%))6 (15)2 (8)4 (25)0.187
Atrial fibrillation (n (%))5 (12)2 (8)3 (19)0.362
Abbreviations: BMI—body mass index, CAD—coronary artery disease, CCS—Canadian Cardiovascular Society, cm—centimeter, COPD—chronic obstructive pulmonary disease, kg—kilogram, n—number, PAD—peripheral arterial disease, and Q—quartiles.
Table 2. Cine angiography, echocardiographic, and laboratory results.
Table 2. Cine angiography, echocardiographic, and laboratory results.
ParametersWhole Group
n = 41
Group 1
CAD Group
n = 25
Group 2
Non-CAD Group
n = 16
p
Group 1 vs. 2
Cine-angiography results:
Normal angiograms (n (%))16 (39)0 (0)16 (100)-
Epicardial disease25 (61)25 (100)0 (0) -
LMCA (n (%))5 (12)5 (20)0 (0) -
One-vessel (n (%))2 (5)2 (8)0 (0) -
Two-vessel (n (%))10 (24)10 (40)0 (0) -
Three-vessel disease (n (%))8 (20)8 (32)0 (0) -
Echocardiographic results:
LVEDD (mm) (median (Q1–Q3))48 (44–52)49 (46–52)44 (42–50)0.117
RVEDD (mm) (median (Q1–Q3))29 (27–31)29 (27–31)29 (28–31)0.958
LAD (mm) (median (Q1–Q3))36 (33–39)37 (34–39)34 (30–38)0.537
IVS (mm) (median (Q1–Q3))12 (10–13)12 (11–13)12 (10–13)0.494
LVEF (%) (median (Q1–Q3))55 (50–60)50 (50–60)60 (52–62)0.309
LV contractility disturbances (n (%))24 (59)15 (60)9 (56)1.000
IM (grade) mild vs. moderate-severe (n (%))21 (51)/8 (20)10 (40)/5 (20)11 (69)/3 (19)0.682
IT (grade) mild vs. moderate (n (%))30 (73)/5 (12)16 (64)/3 (12)14 (88)/2 (13)1.000
Laboratory tests:
Whole blood count analysis
WBC (109/L) (median (Q1–Q3))6.98 (6.03–8.02)7.51 (6.47–8.86)6.79 (5.68–7.41)0.073
Hb (mmol/L) (median (Q1–Q3))8.9 (8.20–9.40)9.20 (8.40–9.70)8.50 (8.00–9.00)0.051
Hct (%) (median (Q1–Q3))43 (41–45)44 (41–46)41 (40.5–43.3)0.104
Plt (109/L) (median (Q1–Q3))221 (196–264)226 (209–264)221 (180–253)0.479
NLR2.63 (2.09–3.45)2.86 (2.46–3.90)2.09 (1.81–2.66)0.009
MLR0.29 (0.24–0.37)0.28 (0.23–0.36)0.30 (0.26–0.35)0.680
C-reactive protein (mg/L)8 (7–9)8 (7–9)8 (7–9)0.554
Kidney function tests
Creatinine (mmol/L) (median (Q1–Q3))81.0 (73.0–91.0)83 (73–101)77.5 (71.3–89.5)0.454
Liver function tests
ALT (IU/L) (median (Q1–Q3))29 (24.5–38.5)31 (26–42)27.5 (22–33)0.241
Lipidogram
Total cholesterol (mmol/L) (median (Q1–Q3))4.16 (3.52–4.70)3.83 (3.18–4.69)4.37 (3.83–4.76)0.235
LDL (mmol/L) (median (Q1–Q3))2.43 (1.67–3.10)2.45 (1.76–3.17)2.16 (1.697–2.92)0.652
HDL (mmol/L) (median (Q1–Q3))1.22 (1.01–1.56)1.09 (0.91–1.28)1.57 (1.33–1.71)0.010
Triglycerides (mmol/L) (median (Q1–Q3))1.30 (0.94–1.79)1.28 (1.00–1.78)1.39 (0.90–1.79)0.825
TSH (mIU/L)2.5 (1.7–3.2)2.5 (1.6–3.2) 2.6 (1.8–3.1)0.911
Abbreviations: ALT—alanine transaminase, IM—mitral insufficiency, IT—tricuspid insufficiency, IVS—intraventricular septum, Hb—hemoglobin, Hct—hematocrit, HDL—high-density lipoprotein, IU—units, L—liter, LAD—left-atrial diameter, LDL—low-density lipoprotein, LMCA—left main coronary artery, LV—left ventricular, LVEDD—left-ventricular end-diastolic diameter, LVEF—left-ventricular ejection fraction, mIU—microunits, mg—milligram, mmol—millimole, mm—millimeter, MLR—monocyte-to-lymphocyte ratio, NLR—neutrophil-to-lymphocyte ratio, n—number, Plt—platelet count, RVEDD—right-ventricular end-diastolic diameter, TSH—thyroid-stimulating hormone, and WBC—white blood cell count.
Table 3. Metabolomic results regarding acetyl-carnitine plasma concentrations.
Table 3. Metabolomic results regarding acetyl-carnitine plasma concentrations.
Parameters
Carnitine-Type Serum Concentrations [µM]
Whole Group
n = 41
Group 1
CAD Group
n = 25
Group 2
Non-CAD Group
n = 16
p
Group 1 vs. 2
CO-L-Carnitine43.60 (38.80–53.90)43.40 (36.20–57.50)44.65 (39.48–48.90)0.873
C2 L-Acetyl-carnitine8.56 (6.49–10.10)7.49 (4.79–9.23)9.36 (8.57–10.23)0.009 *
C3 ** Propionyl-carnitine0.40 (0.31–0.50)0.40 (0.00–0.51)0.00 (0.00–0.49)0.807
C3-DC(C4-OH) Malonyl-carnitine **0.07 (0.00–0.09)0.07 (0.00–0.09)0.07 (0.00–0.09)0.579
C4 Isobutyryl-L-carnitine/Butyryl-carnitine0.23 (0.23–0.33)0.23 (0.18–0.33)0.23 (0.21–0.32)0.936
C4:1 Butenyl-carnitine0.04 (0.04–0.05)0.04 (0.04–0.05)0.04 (0.03–0.05)0.640
C5 2-Methylbutyroyl-carnitine/Isovaleryl-carnitine/Valeryl-carnitine/Pivaloyl-carnitine0.15 (0.13–0.19)0.15 (0.12–0.20)0.15 (0.13–0.20)0.936
C5-DC (C6-OH) Glutaryl-carnitine0.04 (0.03–0.05)0.04 (0.03–0.04)0.05 (0.04–0.06)0.164
C5-OH (C3-DC-M) Hydroxyvaleryl-carnitine/Methylmalonyl-carnitine0.08 (0.07–0.08)0.08 (0.07–0.08)0.07 (0.07–0.08)0.267
C8 Octanoyl-carnitine **0.00 (0.00–0.25)0.00 (0.00–0.21)0.22 (0.00–0.27)0.086
C10 Decanoyl-carnitine **0.31 (0.00–0.40)0.00 (0.00–0.37)0.36 (0.19–0.44)0.040 *
C10:2 2-trans,4-cis-Decadienoyl-carnitine0.05 (0.04–0.05)0.04 (0.04–0.05)0.05 (0.04–0.05)0.067
C12:1 trans-2-Dodecenoyl-carnitine **0.19 (0.15–0.22)0.17 (0.13–0.20)0.22 (0.18–0.24)0.008 *
C14:1 cis-5-Tetradecenoyl-carnitine0.10 (0.08–0.14)0.10 (0.07–0.13)0.13 (0.10–0.15)0.002 *
C14:2 3,5-Tetradecadien-carnitine **0.03 (0.03–0.05)0.03 (0.02–0.04)0.04 (0.03–0.05)0.043
C18:1 Oleoyl-carnitine/Vaccenyl-carnitine/Elaidic-carnitine0.17 (0.15–0.19)0.16 (0.14–0.18)0.18 (0.17–0.27)0.007 *
C18:2 Linoelaidyl-carnitine/Linoleyl-carnitine0.05 (0.04–0.06)0.05 (0.04–0.06)0.05 (0.05–0.07)0.698
* statistically significant. ** the values that did not reach the LOD were corrected to zero. Abbreviations: CO—L-Carnitine; C2—L-Acetyl-carnitine; C3—Propionyl-carnitine; C3-DC(C4-OH)—Malonyl-carnitine; C4—Isobutyryl-L-carnitine/Butyryl-carnitine; C4:1—Butenyl-carnitine; C5 2—Methylbutyroyl-carnitine/Isovaleryl-carnitine/Valeryl-carnitine /Pivaloyl-carnitine; C5-DC (C6-OH)—Glutaryl-carnitine; C5-OH (C3-DC-M)—Hydroxyvaleryl-carnitine/Methylmalonyl-carnitine; C8—Octanoyl-carnitine; C10—Decanoyl-carnitine; C10:2—2-trans,4-cis-Decadienoyl-carnitine; C12:1—trans-2-Dodecenoyl-carnitine; C14:1—cis-5-Tetradecenoyl-carnitine; C14:2—3,5-Tetradecadien-carnitine; C18:1—Oleoyl-carnitine/Vaccenyl-carnitine/Elaidic-carnitine; C18:2—Linoelaidyl-carnitine/Linoleyl-carnitine; n—number; µM—micrometer.
Table 4. The correlation between acetyl-carnitine and the male CAD group.
Table 4. The correlation between acetyl-carnitine and the male CAD group.
AcetylcarnitinesMale CAD Group
Rank-Biserial Correlation
95% CIp
C20.3850.047–0.6440.036 *
C100.5240.219–0.7350.003 *
C12.10.4740.155–0.7030.010 *
C14.10.4670.146–0.6980.011 *
C14.20.285(−) 0.066–0.5730.123
C18.10.3880.050–0.6460.35 *
* statistically significant. Abbreviations: C2—L-Acetyl-carnitine; C10—Decanoyl-carnitine; C12:1—trans-2-Dodecenoyl-carnitine; C14:1—cis-5-Tetradecenoyl-carnitine; C14:2—3, 5-Tetradecadien-carnitine; C18:1—Oleoyl-carnitine/Vaccenyl-carnitine/Elaidic-carnitine.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Urbanowicz, T.; Gutaj, P.; Plewa, S.; Olasińska-Wiśniewska, A.; Spasenenko, I.; Krasińska, B.; Tykarski, A.; Filipiak, K.J.; Pakuła-Iwańska, M.; Krasiński, Z.; et al. The Lower Concentration of Plasma Acetyl-Carnitine in Epicardial Artery Disease—A Preliminary Report. Int. J. Mol. Sci. 2025, 26, 1318. https://doi.org/10.3390/ijms26031318

AMA Style

Urbanowicz T, Gutaj P, Plewa S, Olasińska-Wiśniewska A, Spasenenko I, Krasińska B, Tykarski A, Filipiak KJ, Pakuła-Iwańska M, Krasiński Z, et al. The Lower Concentration of Plasma Acetyl-Carnitine in Epicardial Artery Disease—A Preliminary Report. International Journal of Molecular Sciences. 2025; 26(3):1318. https://doi.org/10.3390/ijms26031318

Chicago/Turabian Style

Urbanowicz, Tomasz, Paweł Gutaj, Szymon Plewa, Anna Olasińska-Wiśniewska, Ievgen Spasenenko, Beata Krasińska, Andrzej Tykarski, Krzysztof J. Filipiak, Martyna Pakuła-Iwańska, Zbigniew Krasiński, and et al. 2025. "The Lower Concentration of Plasma Acetyl-Carnitine in Epicardial Artery Disease—A Preliminary Report" International Journal of Molecular Sciences 26, no. 3: 1318. https://doi.org/10.3390/ijms26031318

APA Style

Urbanowicz, T., Gutaj, P., Plewa, S., Olasińska-Wiśniewska, A., Spasenenko, I., Krasińska, B., Tykarski, A., Filipiak, K. J., Pakuła-Iwańska, M., Krasiński, Z., Grywalska, E., Wender-Ożegowska, E., Jemielity, M., & Matysiak, J. (2025). The Lower Concentration of Plasma Acetyl-Carnitine in Epicardial Artery Disease—A Preliminary Report. International Journal of Molecular Sciences, 26(3), 1318. https://doi.org/10.3390/ijms26031318

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop